This article reflects FDA compounding rules and state med spa regulations as of publication in September 2026. Federal and state law in this area continues to shift. Verify current FDA shortage status and consult with your state medical board or a healthcare attorney before making treatment decisions. Nothing in this article is medical advice for your specific situation.
For two years, roughly 2023 through early 2025, compounded semaglutide was the backbone of weight loss programs at thousands of med spas across the country. When the FDA declared a shortage of semaglutide products in 2022, it opened a legal window that let 503A compounding pharmacies produce copies of the active ingredient for individual patients. Prices came in around $200 to $400 per month for compounded vials versus $900 to $1,300 per month for branded Ozempic or Wegovy. Med spas built entire practice lines around the price differential. Patients built weight loss journeys around access.
That window largely closed in 2025. The FDA declared the tirzepatide shortage resolved on October 2, 2024. Semaglutide followed on February 21, 2025. Once a drug is off the shortage list, 503A pharmacies can no longer routinely compound copies of the FDA-approved product under federal law. In March 2026 alone the FDA sent 30 warning letters to telehealth companies operating in the compounded GLP-1 space. On April 30, 2026, the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B Bulks List entirely, which would further constrain outsourcing facility supply.
This piece covers what med spas can legally prescribe in 2026, what happened to the compounded model, and what a patient considering a med spa GLP-1 program should ask before starting.
What is legal in 2026
Med spas can offer several GLP-1 pathways under current federal law. What is legal depends on the specific product, the pharmacy source, and the patient's clinical situation.
FDA-approved GLP-1 medications are broadly available and legal to prescribe with appropriate physician supervision:
•Ozempic (semaglutide, FDA-approved for Type 2 diabetes)
•Wegovy (semaglutide, FDA-approved for chronic weight management)
•Mounjaro (tirzepatide, FDA-approved for Type 2 diabetes)
•Zepbound (tirzepatide, FDA-approved for chronic weight management)
These are prescribed under a valid patient-provider relationship, dispensed by retail or specialty pharmacies, and administered by the patient or under RN/APRN administration under physician delegation. Prescribing physicians must follow state medical board rules on patient evaluation, informed consent, and documentation.
503B outsourcing facility supply remains legal in a narrower form than during the shortage. 503B outsourcing facilities can produce compounded versions under specific conditions, though the April 2026 FDA proposal to remove GLP-1s from the 503B Bulks List would eliminate most of this supply pathway if finalized.
503A patient-specific compounding remains legal when a prescriber documents a genuine clinical difference the FDA-approved product cannot meet — such as a documented excipient allergy or a strength that is not commercially available. This is a narrow exception. Routine, marketed compounded semaglutide sold to any patient who wants it is not covered by this exception and is not legal under federal law post-shortage.
The "semaglutide with B12" workaround the FDA closed
As soon as the shortage resolved, some compounding pharmacies pivoted to combining semaglutide with vitamin B12 or other additives, arguing that the combination product was not "essentially a copy" of the FDA-approved single-ingredient product. The theory was that the added ingredient created a formulation difference the copy rule did not reach.
In its April 1, 2026 guidance update, the FDA addressed the workaround directly. The FDA stated it may still treat a compounded product combining semaglutide with another active ingredient such as vitamin B12 as essentially a copy when the products use the same route and the amounts of both active ingredients are within 10% of the strengths of the respective commercially available products. The worked example the FDA published closed most of the practical space the workaround had opened.
A formulation change matters for compounding law only when the full legal test is met — clinical difference, not just ingredient addition. Adding a vitamin does not create a clinical difference that makes the compound legal to sell broadly.
State enforcement has stepped up
Federal enforcement is only part of the picture. State medical boards, state pharmacy boards, and state attorneys general have taken significant action against telehealth-only weight loss prescribers and compounding pharmacies in 2025 and 2026. Confirmed enforcement activity includes:
California, New York, Texas, and Florida medical boards have taken disciplinary action against telehealth-only weight loss prescribers in 2025.
FDA warning letters to compounding pharmacies marketing post-shortage GLP-1 copies have continued through 2026.
The Department of Justice has signaled that high-volume cross-state operations may face additional scrutiny under federal fraud and anti-kickback statutes.
Indiana SB 282, which passed the Indiana Senate in January 2026, requires 503A and 503B compounding pharmacies to comply with federal law and authorizes enforcement by the Indiana Board of Pharmacy. The same bill creates a medical spa registration framework effective January 1, 2027 — the first state-level med spa registration framework tied to compounding compliance.
New York, California, Michigan, and other states have issued their own 2026 guidance addressing GLP-1 compounding within their jurisdictions.
The practical result for a patient is that med spas which continue to offer bulk-stocked compounded semaglutide in 2026 are frequently operating in a gray zone with meaningful enforcement risk. The med spa itself may face state medical board action. The compounding pharmacy may face FDA action. The patient may find their program disrupted mid-course if the pharmacy is shut down or the med spa is disciplined.
What a compliant med spa program looks like in 2026
A weight loss program that is likely to be around a year from now generally has these characteristics:
Uses FDA-approved products by default. Ozempic, Wegovy, Mounjaro, and Zepbound are the primary tools. Compounded alternatives, if used, are limited to documented clinical need per 503A rules.
Real prescriber evaluation. The prescribing physician or advanced practice provider conducts a genuine patient evaluation — history, exam, contraindication screening, informed consent — at the same visit as the prescription. State medical boards frequently look at whether the evaluation and prescription happened together.
RN or APRN administration under physician delegation with proper protocols. States vary on scope of practice; a compliant program follows the applicable state's rules on who can administer injections and under what delegation framework.
Ongoing monitoring. Follow-up visits at reasonable intervals, weight and side effect tracking, dose adjustments based on clinical response. A program that prescribes and does not follow up is one that faces additional scrutiny.
Clear pricing. Program costs are disclosed upfront. Whether the patient pays for the medication directly, through the med spa, or through a specialty pharmacy is transparent.
Compliant marketing. The med spa does not claim results the FDA labeling does not support. Marketing does not target patients outside the labeling (patients without diabetes or without qualifying BMI for weight management indications).
What to ask before starting a program
If you are considering a med spa GLP-1 program in 2026, five questions are worth asking before signing:
One: is the medication I will receive FDA-approved, or compounded? If compounded, ask why — the answer should reference a specific clinical reason, not "cost" or "availability."
Two: who is the prescribing provider, and did they personally evaluate me? A prescription without a genuine evaluation is a compliance risk for the med spa and a safety risk for you.
Three: what is the total cost, including medication, visits, and administration? Compare to alternatives — a compliant program using FDA-approved products often costs more per month than a compounded program did in 2023-2024, but the compliance risk profile is different.
Four: what is the plan if the medication becomes unavailable or the pharmacy is disrupted? Programs that source from a single small compounding pharmacy face concentration risk. Ask about the continuity plan.
Five: what is the plan for tapering or discontinuation? GLP-1 medications are typically not intended to be lifelong prescriptions for weight management, and abrupt discontinuation is commonly associated with weight regain. A program without a discontinuation plan is a program that may leave you where you started once the injections stop.
The economics changed, not just the law
For a patient who was paying $250 per month for compounded semaglutide in 2024, the 2026 economics of FDA-approved products are a significant change. Retail prices for Ozempic, Wegovy, Mounjaro, and Zepbound generally run $900 to $1,300 per month before insurance, with variable coverage depending on plan, indication, and prior authorization requirements. Insurance coverage for weight management indications is more restrictive than for diabetes; many plans cover Ozempic for diabetes but not Wegovy for weight loss.
Manufacturer patient assistance programs, direct-to-consumer channels (Novo Nordisk's NovoCare Pharmacy, Eli Lilly's LillyDirect), and specialty pharmacy discount programs are worth investigating before assuming a compliant program is unaffordable. The list price is not the price everyone pays.
Some patients who were on compounded programs will find that a legitimate FDA-approved program is out of reach at their price point. That is a real consequence of the compounding cliff. It is not, however, a reason to seek out compounded programs that continue to operate in defiance of current FDA rules — the enforcement risk on those programs is real and the safety of the compounded product is often unverified.
What is coming next
The April 30, 2026 FDA proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B Bulks List would, if finalized, further constrain the compounded supply pathway. Public comment on the proposal is ongoing. The final rule, when issued, will likely close the remaining 503B pathway for these products and push the market toward FDA-approved products even more decisively.
State-level activity will continue. Additional states are likely to follow Indiana in creating med spa registration frameworks tied to compounding compliance. State medical boards will continue to discipline telehealth-only prescribers with inadequate patient evaluations. The regulatory picture in 2027 is likely to look tighter than 2026, not looser.
For a patient starting a program in 2026, the practical read is: use a med spa that offers FDA-approved products with genuine prescriber evaluation and transparent pricing. The cost is higher than the compounded model that existed for two years. The tradeoff is a program that will still exist next year.
The difference between a compliant program and one that operates in a gray zone matters not just for regulatory reasons but for continuity of your care.
This article is educational and does not constitute medical advice. Always consult a licensed medical professional for personalized recommendations.
Looking for a medical weight loss provider?